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INTRODUCTION 
 
Thyroid diseases are, arguably, among the commonest endocrine 
disorders worldwide. India too, is no exception. According to a projection 
from various studies on thyroid disease, it has been estimated that about 
42 million people in India suffer from thyroid diseases[1]. Thyroid 
diseases are different from other diseases in terms of their ease of 
diagnosis, accessibility of medical treatment, and the relative visibility 
that even a small swelling of the thyroid offers to the treating physician. 
Early diagnosis and treatment remain the cornerstone of management.  
 
By definition, subclinical hypothyroidism refers to patients who 
have an elevated TSH level and a normal free T4 level [2]. Patients with 
subclinical thyroid disease have few or no symptoms or signs of thyroid 
dysfunction and thus, by its very nature, subclinical thyroid disease is a 
laboratory diagnosis. The prevalence of subclinical hypothyroidism in the 
United States adult population is 4–8.5%, although this figure increases 
with age, may differ among ethnic groups and less consistent data is 
available among men. The progression to overt hypothyroidism is 
approximately 2–5% per year[2]. The rate of progression is proportional to 
baseline TSH concentration and is higher in individuals with antithyroid 
antibodies. In India, the prevalence of subclinical hypothyroidism has 
[2] 
 
been estimated to be 9.4%[1]. In the past decade, a number of review 
articles addressing subclinical thyroid disease have been published. They 
have in turn focused on evolving issues regarding definition, diagnosis 
and management of this common condition. It is important to note that 
the literature in this area is still inadequate[3]. 
 
There is substantial evidence that overt hypothyroidism alters 
several of the traditional risk factors for cardiovascular disease. The 
studies in this regard support a biologically plausible role for 
hypothyroidism increasing the risk of atherosclerotic cardiovascular 
diseases, via increases in circulating levels of highly atherogenic low-
density lipoprotein (LDL) cholesterol particles, induction of diastolic 
hypertension, altered coagulability, and direct effects on vascular smooth 
muscle. Furthermore, some evidence suggests that hypothyroidism may 
exacerbate the cardiovascular risks associated with cigarette smoking and 
insulin resistance[4]. 
            
           The association between subclinical hypothyroidism and coronary 
artery disease is not clear. The popular Whickham Survey[5], which 
evaluated vascular events over 20 years in community-dwelling subjects 
stratified by thyroid function and thyroid autoantibody status, found no 
association between ischemic heart disease (IHD) and a composite 
[3] 
 
autoimmune thyroid disease group, comprising individuals with 
subclinical hypothyroidism (SCH), with positive thyroid antibodies or 
those using levothyroxine. This result appears to be at odds with the 
findings of other cohort studies. Reanalysis of the Whickham Survey 
shows an association of subclinical hypothyroidism and heart disease. This 
study, done by Razvi et al. suggests that there is an increased risk of 
cardiac disease and death in those with subclinical hypothyroidism[6].  
           
          CRP is an acute-phase reactant synthesized mainly in the liver. 
Emerging evidence suggests that elevated plasma levels of CRP have 
become one of the strongest independent predictors of CHD[7]. Standard 
clinical assays for CRP typically have a lower detection limit of 3 to 8 
mg/L. Thus, these assays lack sensitivity within the low-normal range and 
cannot be used effectively for vascular risk prediction. 
 
 In recognition of this limitation, initial epidemiological studies 
used research-based assays designed to determine CRP levels with 
excellent fidelity and reproducibility across the normal range. Several 
such “high-sensitivity” or “ultra-sensitive” assays for CRP are now 
commercially available, and formal standardization programs have been 
undertaken to ensure comparability across hs-CRP assays[8]. 
[4] 
 
In our study, we attempted to find out the prevalence of elevated 
levels of high sensitivity CRP in individuals with subclinical 
hypothyroidism, and thereby assessing the risk of developing coronary 
vascular events in future.  
 
 [5] 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
          
         
1. To determine the concentration of high sensitivity C-reactive protein and 
to estimate the prevalence of elevated high sensitivity C-reactive protein 
in individuals with subclinical hypothyroidism and control group. 
2. To correlate the level of hs-CRP with serum TSH, Lipid profile and 
anthropometric parameters. 
3. To risk-categorize the patients for cardiovascular disorders based on hs-
CRP levels. 
 
[6] 
 
REVIEW OF LITERATURE 
 
 
 (A) ANATOMY AND HISTOLOGY OF THE THYROID GLAND[9] 
The thyroid is one of the largest of the endocrine organs, weighing 
approximately 15 to 20 g. The normal thyroid is made up of two lobes 
joined by a thin band of tissue, the isthmus. Two pairs of vessels 
constitute the major arterial blood supply, the superior thyroid artery, 
arising from the external carotid artery, and the inferior thyroid artery, 
arising from the subclavian artery. Estimates of thyroid blood flow range 
from 4 to 6 mL/min/g, well in excess of the blood flow to the kidney (3 
mL/min/g). In diffuse toxic goiter due to Graves' disease, blood flow may 
exceed 1 L/min and be associated with an audible bruit or even a palpable 
thrill. 
The gland is composed of closely packed spherical units termed 
follicles, which are invested with a rich capillary network. The interior of 
the follicle is filled with the clear proteinaceous colloid that normally is 
the major constituent of the total thyroid mass. On cross section, thyroid 
tissue appears as closely packed ring-shaped structures consisting of a 
single layer of thyroid cells surrounding a lumen. The follicular cells vary 
in height with the degree of glandular stimulation, becoming columnar 
when active and cuboidal when inactive. The epithelium rests on a 
[7] 
 
basement membrane that is rich with glycoproteins separating the 
follicular cells from the surrounding capillaries. From 20 to 40 follicles 
are demarcated by connective tissue septa to form a lobule supplied by a 
single artery. The function of a given lobule may differ from that of its 
neighbours. 
On electron microscopy, the thyroid follicular epithelium has many 
features in common with other secretory cells and some peculiar to the 
thyroid. From the apex of the follicular cell, numerous microvilli extend 
into the colloid. It is at or near this surface of the cell that iodination, 
exocytosis, and the initial phase of hormone secretion, namely colloid 
resorption, occur.[10] The nucleus has no distinctive features and the 
cytoplasm contains an extensive endoplasmic reticulum laden with 
microsomes. The endoplasmic reticulum is composed of a network of 
wide irregular tubules that contain the precursor of Tg. The carbohydrate 
component of Tg is added to this precursor in the Golgi apparatus which 
is located apically. Lysosomes and mitochondria are scattered throughout 
the cytoplasm. Stimulation by TSH results in enlargement of the Golgi 
apparatus, formation of pseudopodia at the apical surface, and the 
appearance in the apical portion of the cell of many droplets that contain 
colloid taken up from the follicular lumen. 
 
[8] 
 
(B) Chemical structure of thyroid hormones 
 
                   Figure 1. Chemical structure of thyroid hormones 
 
[9] 
 
 
(C)SYNTHESIS AND SECRETION OF THE THYROID  HORMONES[11] 
 
            About 93 per cent of the metabolically active hormones secreted by the 
thyroid  gland is thyroxine, and 7 per cent triiodothyronine. However, almost all 
the thyroxine is eventually converted to triiodothyronine in the tissues, so that 
both are functionally important. The functions of these two hormones are 
qualitatively the same, but they differ in rapidity and intensity of action. 
Triiodothyronine is about four times as potent as thyroxine, but it is present in 
the blood in much smaller quantities and persists for a much shorter time than 
does thyroxine. 
 
Iodine Is Required for Formation of Thyroxine 
To form normal quantities of thyroxine, about 50 milligrams of ingested iodine 
in the form of iodides are required each year, or about 1 mg/week. To prevent 
iodine deficiency, common table salt is iodized with about 1 part sodium iodide 
to every 100,000 parts sodium chloride. 
             Iodides ingested orally are absorbed from the Gastrointestinal tract into  
the blood. Normally, most of the iodides are rapidly excreted by the kidneys, 
but only after about one fifth are selectively removed from the circulating blood 
by the cells of the thyroid gland and used for synthesis of the thyroid hormones.  
Iodide Pump (Iodide Trapping), the first stage in the formation of thyroid  
[10] 
 
 hormones, is transport of iodides from the blood into the thyroid glandular cells 
and follicles. The basal membrane of the thyroid cell has the specific ability to   
pump the iodide actively to the interior of the cell. This is called iodide 
trapping. In a normal gland, the iodide pump concentrates the iodide to about 30 
times its concentration in the blood. When the thyroid gland becomes 
maximally active, this concentration ratio can rise to as high as 250 times. The 
rate of iodide trapping by the thyroid is influenced by several factors, the most 
important being the concentration of TSH, which stimulates the activity  
of the iodide pump in thyroid cells. The thyroid cells are typical protein-
secreting glandular cells. The endoplasmic reticulum and Golgi apparatus 
synthesize and secrete into the follicles a large glycoprotein molecule called 
thyroglobulin. Each molecule of thyroglobulin contains about 70 tyrosine amino 
acids, and they are the major substrates that combine with iodine to form the 
thyroid hormones. Thus, the thyroid hormones form within the thyroglobulin 
molecule. That is, the thyroxine and triiodothyronine hormones formed from the 
tyrosine amino acids remain part of the thyroglobulin molecule during synthesis 
of the thyroid hormones and even afterward as stored hormones in the follicular 
colloid.  
Oxidation of the Iodide Ion. The first essential step in the formation of the 
thyroid hormones is conversion of the iodide ions to an oxidized form of iodine, 
that is then capable of combining directly with the amino acid tyrosine. This 
oxidation of iodine is promoted by the enzyme peroxidase and its 
[11] 
 
accompanying hydrogen peroxide, which provide a potent system capable of 
oxidizing iodides. 
The peroxidase is either located in the apical membrane of the cell or 
attached to it, thus providing the oxidized iodine at exactly the point in the cell 
where the thyroglobulin molecule issues forth from the Golgi apparatus and 
through the cell membrane into the stored thyroid gland colloid. When the 
peroxidase system is blocked or when it is hereditarily absent from the cells, the 
rate of formation of thyroid hormones falls to zero.  
 Organification of Thyroglobulin. The binding of iodine with the thyroglobulin 
molecule is called organification of the thyroglobulin. Oxidized iodine even in 
the molecular form will bind directly but very slowly with the amino acid 
tyrosine. In the thyroid cells, however, the oxidized iodine is associated with an 
iodinase enzyme that causes the process to occur within seconds or minutes. 
Tyrosine is first iodized to monoiodotyrosine and then to diiodotyrosine. Then, 
during the next few minutes, hours, and even days, more and more of the 
iodotyrosine residues become coupled with one another. 
The major hormonal product of the coupling reaction is the molecule 
thyroxine that remains part of the thyroglobulin molecule. Or one molecule of 
monoiodotyrosine couples with one molecule of diiodotyrosine to form 
triiodothyronine, which represents about one fifteenth of the final hormones. 
 
[12] 
 
Storage of Thyroglobulin.  After synthesis of the thyroid hormones has run its 
course, each thyroglobulin molecule contains up to 30 thyroxine molecules and 
a few triiodothyronine molecules. In this form, the thyroid hormones are stored 
in the follicles in an amount sufficient to supply the body with its normal 
requirements of thyroid hormones for 2 to 3 months. Therefore, when synthesis 
of thyroid hormone ceases, the physiologic effects of deficiency are not 
observed for several months. 
Release of Thyroxine and Triiodothyronine from the Thyroid Gland. 
To get released into circulation, thyroxine and triiodothyronine must first 
be cleaved from the thyroglobulin molecule. This process occurs as follows: 
The apical surface of the thyroid cells sends out pseudopod extensions that close 
around small portions of the colloid to form pinocytic vesicles that enter the 
apex of the thyroid cell. Then lysosomes in the cell cytoplasm immediately fuse 
with these vesicles to form digestive vesicles containing digestive enzymes 
from the lysosomes mixed with the colloid. Multiple proteases among the 
enzymes digest the thyroglobulin molecules and release thyroxine and 
triiodothyronine in free form. These then diffuse through the base of the thyroid 
cell into the surrounding capillaries. Thus, the thyroid hormones are released 
into the blood. 
  About three quarters of the iodinated tyrosine in the thyroglobulin never 
becomes thyroid hormones but remains monoiodotyrosine and diiodotyrosine. 
[13] 
 
During the digestion of the thyroglobulin molecule to cause release of thyroxine 
and triiodothyronine, these iodinated tyrosines also are freed from the 
thyroglobulin molecules. However, they are not secreted into the blood. Instead, 
their iodine is cleaved from them by a deiodinase enzyme that makes virtually 
all this iodine available again for recycling within the gland for forming 
additional thyroid hormones. In the congenital absence of this deiodinase 
enzyme, many persons become iodine-deficient because of failure of this 
recycling process. 
 
Daily Rate of Secretion of Thyroxine and Triiodothyronine. 
About 93 per cent of the thyroid hormone released from the thyroid gland 
is normally thyroxine and only 7 per cent is triiodothyronine. However, during 
the ensuing few days, about one half of the thyroxine is slowly deiodinated to 
form additional triiodothyronine. Therefore, the hormone finally delivered to 
and used by the tissues is mainly triiodothyronine.  
Transport of Thyroxine and Triiodothyronine to Tissues. 
Thyroxine and Triiodothyronine Are Bound to Plasma Proteins. On 
entering the blood, over 99 per cent of the thyroxine and triiodothyronine 
combines immediately with several of the plasma proteins, all of which are 
synthesized by the liver. They combine mainly with thyroxine-binding globulin 
and much less so with thyroxine-binding prealbumin and albumin. Thyroxine 
and Triiodothyronine Are Released Slowly to Tissue Cells. Because of high 
[14] 
 
affinity of the plasma- binding proteins for the thyroid hormones, these 
substances—in particular, thyroxine—are released to the tissue cells slowly.  
(D) MECHANISM OF ACTION[12] 
 
 
Figure 2. Schematic illustration of a follicular cell showing the key aspects of thyroid iodine 
transport and thyroid hormone synthesis. NIS, Sodium-iodide symporter; T3, triiodothyronine; 
T4, thyroxine; Tg, thyroglobulin; TPO, thyroid peroxidase TSHR, thyrotropin receptor[13]. 
Thyroid hormones enter cells and T3 binds to thyroid receptors (TR) in 
the nuclei. T4 can also bind, but not as avidly. The hormone-receptor complex 
then binds to DNA via zinc fingers and increases (or in some cases, decreases) 
[15] 
 
the expression of a variety of different genes that code for proteins that regulate 
cell function. Thus, the nuclear receptors for thyroid hormones are members of 
the superfamily of  hormonesensitive nuclear transcription factors. There are 
two human TR genes: an receptor gene on chromosome 17 and a receptor gene 
on chromosome 3. By alternative splicing, each forms at least two different 
mRNAs and therefore two different receptor proteins. TR 2 is found only in the 
brain, but TR 1, TR 2, and TR 1 are widely distributed. TR 2 differs from the 
other three in that it does not bind T3 and its function is not yet fully 
established. TRs bind to DNA as monomers, homodimers, and heterodimers 
with other nuclear receptors, particularly the retinoid X receptor (RXR). The 
TR/RXR heterodimer does not bind 9-cis retinoic acid, the usual ligand for 
RXR, but TR binding to DNA is greatly enhanced in response to thyroid 
hormones when the receptor is in the form of this heterodimer. There are also 
coactivator and corepressor proteins that affect the actions of TRs. Presumably, 
this complexity underlies the ability of thyroid hormones to produce many 
different effects in the body. In most of its actions, T3 acts more rapidly and is 
three to five times more potent than T4. This is because T3 is less tightly bound 
to plasma proteins than is T4, but binds more avidly to thyroid hormone 
receptors. RT3 is inert.  
 
 
 
 
[16] 
 
(E) PHYSIOLOGIC FUNCTIONS OF THE THYROID HORMONES [12] 
 
Some of the widespread effects of thyroid hormones in the body are 
secondary to stimulation of O2 consumption (calorigenic action), although the 
hormones also affect growth and development in mammals, help regulate lipid 
metabolism, and increase the absorption of carbohydrates from the intestine . 
They also increase the dissociation of oxygen from hemoglobin by increasing 
red cell 2,3-diphosphoglycerate (DPG). 
1. CALORIGENIC ACTION 
T4 and T3 increase the O2 consumption of almost all metabolically active 
tissues. The exceptions are the adult brain, testes, uterus, lymph nodes, spleen, 
and anterior pituitary. T4 actually depresses the O2 consumption of the anterior 
pituitary, presumably because it inhibits TSH secretion. The increase in 
metabolic rate produced by a single dose of T4 becomes measurable after a 
latent period of several hours and lasts 6 days or more. Some of the calorigenic 
effect of thyroid hormones is due to metabolism of the fatty acids they mobilize. 
In addition, thyroid hormones increase the activity of the membrane-bound Na, 
K ATPase in many tissues.  
EFFECTS SECONDARY TO CALORIGENESIS 
When the metabolic rate is increased by T4 and T3 in adults, nitrogen 
excretion is increased; if food intake is not increased, endogenous protein and 
[17] 
 
fat stores are catabolized and weight is lost. In hypothyroid children, small 
doses of thyroid hormones cause a positive nitrogen balance because they 
stimulate growth, but large doses cause protein catabolism similar to that 
produced in the adult. The potassium liberated during protein catabolism 
appears in the urine, and there is also an increase in urinary hexosamine and 
uric acid excretion. 
When the metabolic rate is increased, the need for all vitamins is 
increased and vitamin deficiency syndromes may be precipitated. Thyroid 
hormones are necessary for hepatic conversion of carotene to vitamin A, and the 
accumulation of carotene in the bloodstream (carotenemia) in hypothyroidism is 
responsible for the yellowish tint of the skin. Carotenemia can be distinguished 
from jaundice because in the former condition the scleras are not yellow. 
The skin normally contains a variety of proteins combined with 
polysaccharides, hyaluronic acid, and chondroitin sulfuric acid. In 
hypothyroidism, these complexes accumulate, promoting water retention and 
the characteristic puffiness of the skin (myxedema). When thyroid hormones are 
administered, the proteins are metabolized, and diuresis continues until the 
myxedema is cleared. 
Milk secretion is decreased in hypothyroidism and stimulated by thyroid 
hormones, a fact sometimes put to practical use in the dairy industry. Thyroid 
[18] 
 
hormones do not stimulate the metabolism of the uterus but are essential for 
normal menstrual cycles and fertility. 
2. EFFECTS ON THE NERVOUS SYSTEM 
In hypothyroidism, mentation is slow and the cerebrospinal fluid (CSF) 
protein level elevated. Thyroid hormones reverse these changes, and large doses 
cause rapid mentation, irritability, and restlessness. Overall, cerebral blood flow 
and glucose and O2 consumption by the brain are normal in adult hypo- and 
hyperthyroidism. However, thyroid hormones enter the brain in adults and are 
found in gray matter in numerous different locations. In addition, astrocytes in 
the brain convert T4 to T3, and there is a sharp increase in brain D2 activity 
after thyroidectomy that is reversed within 4 h by a single intravenous dose of 
T3. Some of the effects of thyroid hormones on the brain are probably 
secondary to increased responsiveness to catecholamines, with consequent 
increased activation of the reticular activating system. In addition, thyroid 
hormones have marked effects on brain development. The parts of the central 
nervous system (CNS) most affected are the cerebral cortex and the basal 
ganglia. In addition, the cochlea is also affected. Consequently, thyroid 
hormone deficiency during development causes mental retardation, motor 
rigidity, and deaf–mutism. Deficiencies in thyroid hormone synthesis secondary 
[19] 
 
to a failure of thyrocytes to transport iodide presumably also contribute to 
deafness in Pendred syndrome, discussed above. 
Thyroid hormones also exert effects on reflexes. The reaction time of 
stretch reflexes is shortened in hyperthyroidism and prolonged in 
hypothyroidism. Measurement of the reaction time of the ankle jerk (Achilles 
reflex) has attracted attention as a clinical test for evaluating thyroid function, 
but this reaction time is also affected by other diseases and thus is not a specific 
assessment of thyroid activity.  
3. RELATION TO CATECHOLAMINES 
The actions of thyroid hormones and the catecholamines norepinephrine 
and epinephrine are intimately interrelated. Epinephrine increases the metabolic 
rate, stimulates the nervous system, and produces cardiovascular effects similar 
to those of thyroid hormones, although the duration of these actions is brief. 
Norepinephrine has generally similar actions. The toxicity of the 
catecholamines is markedly increased in rats treated with T4 . Although plasma 
catecholamine levels are normal in hyperthyroidism, the cardiovascular 
effects, tremulousness, and sweating produced by thyroid hormones can be 
reduced or abolished by sympathectomy. They can also be reduced by drugs 
such as propranolol that block -adrenergic receptors. Indeed, propranolol and 
other blockers are used extensively in the treatment of thyrotoxicosis and in the 
[20] 
 
treatment of the severe exacerbations of hyperthyroidism called thyroid storms. 
However, even though blockers are weak inhibitors of extrathyroidal conversion 
of T4 to T3, and consequently may produce a small fall in plasma T3, they have 
little effect on the other actions of thyroid hormones. Presumably, the functional 
synergism observed between catecholamines and thyroid hormones, particularly 
in pathological settings, arises from their overlapping biological functions as 
well as the ability of thyroid hormones to increase expression of catecholamine 
receptors and the signaling effectors to which they are linked. 
4. EFFECTS ON SKELETAL MUSCLE 
Muscle weakness occurs in most patients with hyperthyroidism 
(thyrotoxic myopathy), and when the hyperthyroidism is severe and prolonged, 
the myopathy may be severe. The muscle weakness may be due in part to 
increased protein catabolism. Thyroid hormones affect the expression of the 
MHC genes in skeletal as well as cardiac muscle. However, the effects 
produced are complex and their relation to the myopathy is not established. 
Hypothyroidism is also associated with muscle weakness, cramps, and stiffness. 
5. EFFECTS ON CARBOHYDRATE METABOLISM 
Thyroid hormones increase the rate of absorption of carbohydrates from 
the gastrointestinal tract, an action that is probably independent of their 
calorigenic action. In hyperthyroidism, therefore, the plasma glucose level rises 
[21] 
 
rapidly after a carbohydrate meal, sometimes exceeding the renal threshold. 
However, it falls again at a rapid rate. 
6. EFFECTS ON GROWTH 
Thyroid hormones are essential for normal growth and skeletal 
maturation . In hypothyroid children, bone growth is slowed and epiphysial 
closure delayed. In the absence of thyroid hormones, growth hormone secretion 
is also depressed. This further impairs growth and development, since thyroid 
hormones normally potentiate the effect of growth hormone on tissues. 
7. EFFECTS ON THE CARDIOVASCULAR SYSTEM 
Large doses of thyroid hormones cause enough extra heat production to 
lead to a slight rise in body temperatures, which in turn activates heat-
dissipating mechanisms. Peripheral resistance decreases because of cutaneous 
vasodilation, and this increases levels of renal Na+ and water absorption, 
expanding blood volume. Cardiac output is increased by the direct action of 
thyroid hormones, as well as that of catecholamines, on the heart, so that pulse 
pressure and cardiac rate are increased and circulation time is shortened. 
T3 is not formed from T4 in myocytes to any degree, but circulatory T3 
enters the myocytes, combines with its receptors, and enters the nucleus, where 
it promotes the expression of some genes and inhibits the expression of others. 
Those that are enhanced include the genes for -myosin heavy chain, 
[22] 
 
sarcoplasmic reticulum Ca2+ ATPase, -adrenergic receptors, G proteins, Na, K 
ATPase, and certain K+ channels. Those that are inhibited include the genes for 
-myosin heavy chain, phospholamban, two types of adenylyl cyclase, T3 
nuclear receptors, and NCX, the Na+–Ca2+ exchanger. The net result is 
increased heart rate and force of contraction. 
8. EFFECTS ON CHOLESTEROL METABOLISM 
Thyroid hormones lower circulating cholesterol levels. The plasma 
cholesterol level drops before the metabolic rate rises, which indicates that this 
action is independent of the stimulation of O2 consumption. The decrease in 
plasma cholesterol concentration is due to increased formation of low-density 
lipoprotein (LDL) receptors in the liver, resulting in increased hepatic removal 
of cholesterol from the circulation. Despite considerable effort, however, it has 
not been possible to produce a clinically useful thyroid hormone analog that 
lowers plasma cholesterol without increasing metabolism. 
(F) HYPOTHYROIDISM 
Many structural or functional abnormalities can impair the production of 
thyroid hormones and cause the clinical state termed hypothyroidism. The 
causes can be divided into six main categories[9]:  
   1.    Hypothyroidism with compensatory thyroid enlargement due to transient 
[23] 
 
or progressive impairment of hormone biosynthesis (goitrous 
hypothyroidism).  
   2.    Permanent loss or atrophy of thyroid tissue (atrophic hypothyroidism).  
   3.    Transient hypothyroidism.  
   4.    Consumptive hypothyroidism.  
   
5.    Central hypothyroidism, that is, hypothyroidism due to insufficient 
stimulation of a normal gland as a result of hypothalamic or pituitary 
disease or defects in the thyroid-stimulating hormone (TSH) molecule 
itself.  
   6.    Resistance to thyroid hormone (RTH).  
Epidemiology 
Global Prevalence: 
Primary hypothyroidism accounts for approximately 99% of cases, with 
fewer than 1% being due to TSH deficiency. Comparison of studies of the 
prevalence and incidence of hypothyroidism is hampered by differing 
definitions and population samples. Using a uniform set of diagnostic criteria, 
the prevalence of previously undiagnosed, spontaneous, overt hypothyroidism 
in community-based studies has been estimated between 2-4/1000 total 
population world-wide. If all cases of previously diagnosed hypothyroidism, 
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previous thyroid surgery and radioiodine treatment are included, this prevalence 
rises to approximately 10/1000, and if subclinical cases are included, then the 
prevalence is probably over 50/1000 total population. The annual incidence of 
overt hypothyroidism is between 1-2/1000 for female and around 2/10,000 for 
males, with individuals having previously elevated TSH and positive circulating 
thyroid autoantibodies, being particularly at risk[14]. 
Prevalence in India : 
Among adult people in India, the prevalence of hypothyroidism has been 
recently studied. In this population-based study done in Cochin on 971 adult 
subjects, the prevalence of hypothyroidism was 3.9%[1]. The prevalence of 
subclinical  hypothyroidism was also high in this study, the value being 9.4%. 
In women, the prevalence was higher, at 11.4%, when compared with men, in 
whom the prevalence was 6.2%. The prevalence of subclinical hypothyroidism 
increased with age. About 53% of subjects with subclinical hypothyroidism 
were positive for anti-TPO antibodies 
Clinical Features[15] 
Signs and Symptoms of Hypothyroidism (Descending Order of Frequency) 
Symptoms 
 Tiredness, weakness 
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 Dry skin 
 Feeling cold 
 Hair loss 
 Difficulty concentrating and poor memory 
 Constipation 
 Weight gain with poor appetite 
 Dyspnea 
 Hoarse voice 
 Menorrhagia (later oligomenorrhea or amenorrhea) 
 Paresthesia 
 Impaired hearing 
Signs 
 Dry coarse skin; cool peripheral extremities 
 Puffy face, hands, and feet (myxedema) 
 Diffuse alopecia 
 Bradycardia 
 Peripheral edema 
 Delayed tendon reflex relaxation 
 Carpal tunnel syndrome 
 Serous cavity effusions 
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SUBCLINICAL HYPOTHYROIDISM 
(a)Definition[3] 
Subclinical hypothyroidism is defined as “a serum thyroid stimulating hormone 
(TSH) above the defined upper limit of the reference range, with a serum free 
thyroxine (T4) within the reference range”. 
                       Other terms for this condition are mild hypothyroidism, 
preclinical hypothyroidism, biochemical hypothyroidism, and decreased thyroid 
reserve. The TSH elevation in such patients is modest, with values typically 
between 5 and 15 mU/L[9]. This syndrome is most often seen in patients with 
early Hashimoto's disease and is a common phenomenon, occurring in 7% to 
10% of older women. 
(b) Epidemiology 
In population-based studies, the prevalence of subclinical hypothyroidism 
ranges from 4 to 15 percent [17-21]. In the United States National Health and 
Examination Survey (NHANES III), which excluded subjects with known 
thyroid disease, 4.3 percent of 16,533 people had subclinical hypothyroidism. 
The prevalence rises with age, is higher in females than males, and is lower in 
blacks than in whites . However, the prevalence is determined by the upper limit 
of normal for serum TSH. If the upper limit of normal rises with age, as appears 
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to be the case, then the prevalence may not be as high as has been previously 
thought. 
In Europe, where iodine intake is variable, subclinical hypothyroidism is 
more prevalent in areas of iodine sufficiency. In one study, the prevalence of 
subclinical hypothyroidism ranged from 4.2 percent in iodine-deficient areas to 
23.9 percent in an area of abundant iodine intake, despite a similar prevalence 
of patients with high serum concentrations of anti-thyroid peroxidase antibodies 
[22]. 
In India, the prevalence of subclinical hypothyroidism has been estimated 
to be 9.4%[1]. In a study conducted by Gayatri et al[23], the prevalence of  
subclinical hypothyroidism in asymptomatic pregnant women attending 
outpatient department, was 2.8% which corroborated with that of western 
literature. 
(c) Causes[16] 
1.  Chronic autoimmune thyroiditis 
2. Persistent TSH increase in  
          a.subacute thyroiditis 
          b. postpartum thyroiditis 
          c. painless thyroiditis 
3. Thyroid injury 
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          a. partial thyroidectomy or other neck surgery, 
          b. radioactive iodine therapy 
          c. external radiotherapy of the head and neck 
4. Drugs impairing thyroid function: 
a.iodine and iodine-containing medications (amiodarone, radiographic    
contrast agents) 
          b. lithium carbonate 
         c. cytokines (especially interferon) 
         d. aminoglutetimide, 
         e. ethionamide 
         f. sulfonamides 
         g. sulfonylureas 
5. Inadequate replacement therapy for overt hypothyroidism 
6. Thyroid infiltration  
a. Amyloidosis 
 b. Sarcoidosis 
 c. Hemochromatosis 
d. Riedel’s thyroiditis 
 e. Cystinosis 
 f. AIDS 
g. primary thyroid lymphoma 
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7. Central hypothyroidism with impaired TSH bioactivity 
8. Toxic substances, industrial and environmental agents 
9. TSH receptor gene mutations 
(d) Diagnosis 
Patients with subclinical thyroid disease have few or no symptoms or 
signs of thyroid dysfunction and thus by its very nature, subclinical thyroid 
disease is a laboratory diagnosis[3]. The reference normal range for TSH, Free 
T4 and Free T3 taken for this study is as follows(1): 
                            
                                 TSH         :         0.34–4.25 mIU/L 
                                 Free T4     :           0.7–1.24 ng/dL 
                                 Free T3     :           2.4–4.2 pg/mL 
 
(e) Potential Complications 
1. Progression to Overt Hypothyroidism.  
In the experience of most clinicians, that process of progression from 
early thyroid failure to overt hypothyroidism has been slow. This general 
pattern has prompted most experts to recommend monitoring of the serum TSH 
concentration at intervals of 6 to 12 months.[24,25] Several longitudinal studies 
have examined the factors associated with progression.[26] In a recent study, 82 
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women with subclinical hypothyroidism underwent follow-up for a mean of 9.2 
years.[27] Patients were classified into 3 groups on the basis of their initial TSH 
values—4 to 6, 6 to 12, and greater than 12 µIU/mL—and the 10-year incidence 
of hypothyroidism was 0%, 42.8%, and 76.9%, respectively, in those 3 groups. 
The rate of progression to overt hypothyroidism was significantly faster in those 
women with a higher baseline serum TSH concentration. The presence of anti-
TPO antibodies also correlated with a significantly increased incidence of 
progression to overt hypothyroidism. The influence of the magnitude of the 
antibody elevation has not been specifically studied. On the basis of these 
criteria, our patient had a likelihood of progression to overt hypothyroidism of 
approximately 5% per year. 
2. Association with Dyslipoproteinemia and Atherosclerosis 
A relationship between dyslipidemia and atherosclerosis is well 
established in overt hypothyroidism [28]. Early clinical and autopsy studies have 
suggested an association between subclinical hypothyroidism and coronary 
heart disease [29,30]. Furthermore, in a recent population-based survey, 
subclinical hypothyroidism emerged as an independent risk factor for aortic 
atherosclerosis and myocardial infarction [31]. However, the association of SCH 
with changes in serum lipid levels and the effect of l-T4 replacement on these 
changes are still open questions, despite the fact that several clinical trials have 
addressed the issue. In some large epidemiological studies, no association could 
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be detected between SCH and serum TC or LDLc levels.Tzotzas et al. [31] 
recently reported that none of the commonly measured lipoproteins differed 
between SCH patients and controls, nor did the lipoprotein profile change 
significantly in SCH patients upon achieving euthyroidism. In contrast, Caron et 
al.[32] reported lower HDLc levels in SCH patients than in a control group and 
demonstrated a significant increase in ApoA and HDLc levels after l-T4 
therapy,with normalization of the TC/HDLc ratio. Arem and Patsch 
[33], on the other hand, reported a reduction in LDLc, ApoB,and the TC/HDL 
ratio after l-T4 replacement in a group of SCH patients with a mean TSH level 
of 16.6 mIU/liter. Recently, a double-blind, placebo-controlled trial [34] demon- 
strated the effectiveness of l-T4 replacement therapy in both reducing LDL 
cholesterol levels and improving clinical symptoms of hypothyroidism in SCH 
patients. Moreover, LDLc decrease was more pronounced in SCH patients with 
high TSH values (12 mIU/liter) or elevated pretreatment LDLc levels 
(4.0mmol/liter). These rather disparate results may depend on differences in 
patient selection (e.g. cause and duration of thyroid dysfunction, range of TSH 
values, smoking status) as well as time of evaluation after restoration of 
euthyroidism[35]. 
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Atherosclerosis 
The relationship between subclinical hypothyroidism and the later 
development of atherosclerosis is unclear.[36,37,38] The Whickham survey found 
no relationship between initial TSH levels and the subsequent development of 
ischemic heart disease over 20 years of followup.[38] 
A widely publicized population-based study of 1,149 women aged 55 or 
older from Rotterdam came to a different conclusion.[37] The main analysis in 
the paper was cross-sectional. In that analysis, after adjustment for age, body 
mass index, cholesterol level, blood pressure, and smoking status, a serum TSH 
greater than 4.0 mU/L was associated with a history of myocardial infarction 
(OR, 2.3; CI, 1.3-4.2) and with atherosclerosis of the abdominal aorta, which 
was diagnosed by blinded review of a lateral radiograph of the lumbar spine 
(OR, 1.9; CI, 1.2-3.1). An analysis of incident myocardial infarction over 3 to 6 
years of followup found a statistically non-significant increased risk in women 
with a serum TSH greater than 4.0 mU/L (adjusted relative risk, 2.5; CI, 0.7-
9.1). 
The strengths of the Rotterdam study are the relatively large sample size, 
adjustment for some potential confounders, and validated, blinded assessment 
of outcomes. Because the study was primarily cross-sectional, however, the 
findings do not prove that an elevated TSH precedes the development of 
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atherosclerosis. The prospective part of the study adds little because, at baseline, 
the women who had an elevated TSH had a higher prevalence of atherosclerotic 
disease; they would be expected to have a higher incidence of myocardial 
infarction over 3 to 6 years, in any case. The prospective analysis would have 
been more consequential if patients who had atherosclerosis at baseline had 
been excluded.  
In the Rotterdam study, women with subclinical hypothyroidism had 
lower lipid levels than euthyroid women; this might be an artifact of higher use 
of diet or other lipid-lowering therapy in women with known cardiovascular 
risk factors, but it also might suggest that atherosclerosis developed by another 
mechanism. One hypothesis is that elevations in both homocysteine and 
cholesterol may contribute to the elevated risk for atherosclerosis in overt 
hypothyroidism. In cross-sectional studies, including an analysis of the Second 
National Health and Nutrition Examination Survey (NHANES-II) sample, 
patients with overt hypothyroidism had higher homocysteine levels than 
euthyroid patients.[39,40] The association of elevated homocysteine and overt 
hypothyroidism appears to persist after controlling for serum folate levels, 
which are decreased in overt hypothyroidism.[41,42,43] However, in the only study 
concerning patients who had subclinical hypothyroidism, there was no 
association.[44] 
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3. Symptoms, mood, and quality of life.  
In its 1998 review and guideline, the American College of Physicians 
concluded that, in the general population, it was not clear if the prevalence and 
severity of symptoms and quality of life differs for individuals who have mildly 
elevated TSH levels[45,46]. Since then, 2 cross-sectional studies in volunteers 
have addressed this question, with mixed results. A cross-sectional interview 
survey of 825 Medicare enrollees in New Mexico found no differences in the 
age-adjusted frequency of self-reported symptoms between participants with 
serum TSH elevations from 4.7 to 10 mU/L and those with normal TSH 
concentrations.[47] A larger survey from Colorado (n = 25,862) is less pertinent 
because it included subjects who took levothyroxine in the analysis of 
symptoms. It also found no difference between euthyroid subjects and those 
with subclinical hypothyroidism in current symptoms, but found a higher 
percentage of “changed symptoms” in the subclinical hypothyroid group (13.4% 
vs 15.4%).[48] 
Patients who have subclinical hypothyroidism and a history of antithyroid 
treatment for Graves' disease or nodular thyroid disease have a higher 
prevalence of symptoms than healthy controls. [49,50] It is likely that this 
observation is valid, but an important limitation of the evidence should be 
noted: the appropriate comparison group is not healthy volunteers, but patients 
who have a normal TSH and a history of antithyroid treatment. The reason is 
[35] 
 
that euthyroid patients who have a history of treatment for hyperthyroidism also 
have a higher prevalence of anxiety, depression, and psychosocial dysfunction 
than healthy controls.[51] 
 
4. Pregnancy complications.  
Three recent reports from a cohort study of pregnant women have linked 
TSH levels in pregnancy to poor obstetric outcomes and to poor cognitive 
development in children. In the first report, among 9,403 women with singleton 
pregnancies, serum TSH measurements were 6 mU/l or greater in 209 women 
(2.2%). [52] The rate of fetal death was significantly higher in those pregnancies 
(3.8%) than in the women with serum TSH less than 6 mU/l (0.9%, OR, 4.4; 
95% CI, 1.9–9.5). In the second report, the children of women who had a high 
serum TSH (mean 13.2 ± 0.3 mU/L) in the first trimester of pregnancy had 
lower IQ scores than matched controls (mean serum TSH 1.4 ± 0.2 mU/L) when 
they were 7 to 9 years of age. [53] The average difference in IQ was 7 points; 
19% of the children of hypothyroid mothers had IQ scores of 85 or less. 
Although no statistical adjustment for baseline differences was done, at 
baseline, age, socioeconomic status, and other risk factors for low IQ were 
similar in the 2 groups. Results for the subgroup who had subclinical 
hypothyroidism were not broken out, but most of the women fell into this 
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category (that is, they had normal T4 levels).The third report from these authors 
analyzed TSH levels by outcomes. Fifty percent of the children of 20 mothers 
who had a TSH equal to or higher than the 99.85 percentile had IQ scores 
greater than 1 standard deviation (SD) below the control mean. Fifteen percent 
of the children of controls, and 21 percent of the children of women who had a 
TSH between the 98 and 99.85 percentile, had IQ scores this low.  
(f) Management of Subclinical hypothyroidism[54] 
 
Figure 3. Algorithm for the management of subclinical hypothyroidism. (T4 = thyroxine; 
TSH = thyrotropin-stimulating hormone) 
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Indications for treatment in subclinical hypothyroidism are not 
established, but general guidelines can be offered. Greater magnitude and 
duration of TSH elevation and higher titers of antithyroid antibodies increase 
the probability that the condition will progress to overt hypothyroidism and, 
therefore, increase the potential benefit of treatment with levothyroxine. The 
presence of symptoms that might be related to mild hypothyroidism also 
increases the potential benefit of treatment. Risk of harm to the patient, against 
which this potential benefit must be balanced, is quite small, since the use of the 
sensitive TSH assay provides assurance that we are not raising the blood thyroid 
hormone levels too much as long as TSH levels do not fall below the normal 
range. In patients with coronary artery disease and minimal elevations of TSH, 
however, it may be advisable to follow the TSH level rather than subject the 
patient to the small risk of levothyroxine therapy. 
In short, it seems reasonable to treat patients who have a TSH level that is 
consistently elevated above 10 μU per mL (10 mU per L), especially if titers of 
antithyroid antibodies are increased. Also, patients who complain of fatigue, dry 
skin, constipation, muscle cramps or other common symptoms of 
hypothyroidism may possibly benefit from treatment even if their TSH level is 
elevated only into the 5 to 10 μU per mL (5 to 10 mU per L) range. An 
algorithm summarizing this approach is presented in Figure 3. 
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Management in Pregnancy[55] 
There is only fair evidence to support an association between subclinical 
hypothyroidism and adverse outcomes in pregnancy. However, the consensus 
panel[56]. recommends screening serum TSH levels in patients who are pregnant 
or who are planning to become pregnant when there is a family or personal 
history of thyroid disease, evidence of goiter, symptoms of hypothyroidism, 
type 1 diabetes, or a personal history of autoimmune disorder. 
Although there are few data, the panel recommends treatment with 
levothyroxine during pregnancy to maintain serum TSH levels within the 
reference range, with repeat testing every six to eight weeks. Physiologic 
requirements of levothyroxine often increase during pregnancy; therefore, 
women who were receiving therapeutic replacement dosages before becoming 
pregnant should have their serum TSH level monitored every six to eight weeks 
during pregnancy.[56] 
Treatment 
Treatment is similar to that recommended in patients with overt 
hypothyroidism. Levothyroxine is the agent of choice, rather than a preparation 
containing tri-iodothyronine (T3), since T3 has a short half-life and requires 
multiple daily doses to maintain blood levels in the normal range. 
Levothyroxine, however, has a long half-life (approximately seven days) and is 
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partially converted to T3 in the body, resulting in a constant physiologic blood 
level of both T4 and T3 with a single daily dose.[57] 
In patients with overt hypothyroidism, the average daily replacement 
dosage of levothyroxine is 75 to 125 μg, or 50 to 100 μg in the elderly, or about 
1.6 μg per kg per day. Treatment is commonly initiated with 25 to 50 μg daily 
and raised by increments of 25 to 50 μg, according to TSH measurements at six- 
to eight-week intervals. In patients who are elderly or debilitated, or who have 
heart disease, lower starting dosages and slower increases are advisable. 
Patients with subclinical hypothyroidism, because of the minimal extent 
of the thyroid hormone deficiency, may be controlled with total daily dosages of 
levothyroxine as low as 25 to 50 μg. This initial dosage should be maintained 
for six to eight weeks before a TSH measurement is repeated to guide 
adjustment of the levothyroxine dosage. The goal is to maintain the TSH level 
within normal limits; the dosage of levothyroxine should be increased if the 
TSH level remains above normal and should be decreased if the TSH level falls 
below normal. Once the correct dosage of thyroxine is established, the 
frequency of TSH measurement may be decreased to every six to 12 months. 
A common error is the failure to decrease the levothyroxine dosage if the 
TSH level is suppressed below the normal range, which may occur without the 
free T4 level rising above normal. This state is considered to represent 
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“subclinical hyperthyroidism,” and although formerly it was thought to be 
harmless, it is now believed to be associated with undesired effects on bone 
density (osteoporosis) and cardiac function, and to be a possible cause of 
neuropsychologic symptoms and other mild manifestations of 
hyperthyroidism.[58,59] 
 
C-REACTIVE PROTEIN 
C-reactive protein (CRP) is a protein found in the blood, the levels of 
which rise in response to inflammation (i.e. C-reactive protein is an acute-phase 
protein). Its physiological role is to bind to phosphocholine expressed on the 
surface of dead or dying cells (and some types of bacteria) in order to activate 
the complement system via the C1Q complex.[60] 
CRP is synthesized by the liver[61] in response to factors released by fat 
cells (adipocytes).[62] It is a member of the pentraxin family of proteins.  It is not 
related to C-peptide or protein C. C-reactive protein was the first pattern 
recognition receptor (PRR) to be identified.[63]  
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History and nomenclature 
CRP was so named because it was first discovered as a substance in the 
serum of patients with acute inflammation that reacted with the C- (capsular) 
polysaccharide of pneumococcus. 
Discovered by Tillett and Francis in 1930 [64], it was initially thought that 
CRP might be a pathogenic secretion as it was elevated in people with a variety 
of illnesses including cancer, however, discovery of hepatic synthesis 
demonstrated that it is a native protein.[65]  
Molecular Structure 
 
                     Figure 4. Molecular structure of C-Reactive Protein 
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The human crp gene is located on chromosome 1q23[66], and consists of 
two exons and one intron.[67] CRP is synthesized as a 206 amino acid 
polypeptide and secreted by hepatocytes as an approximately 23 κDa, non-
glycosylated monomer, which non-covalently associates to form the 
homopentameric ring structure characteristic of pentraxin family members. CRP 
molecule folds to form a flattened jellyroll structure, which then assembles into 
a radially symmetrical pentamer. (Figure 4). 
 
 
ASSOCIATIONS OF CRP WITH ATHEROSCLEROSIS 
         Our understanding of atherosclerosis has evolved beyond the view that 
these lesions consist of a lifeless collection of lipid debris. Current evidence 
supports a central role for inflammation in all phases of the atherosclerotic 
process. Substantial biological data implicate inflammatory pathways in early 
atherogenesis, in the progression of lesions, and finally in the thrombotic 
complications of this disease. Clinical studies affirm correlation of circulating 
markers of inflammation with propensity to develop ischemic events and with 
prognosis after ACS[68]. 
 CRP: A NOVEL, PROATHEROGENIC INFLAMMATORY 
 ADIPOKINE 
 
Adipokines are mediators of endothelial injury And atherosclerosis. 
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CRP is not merely an inflammatory marker but directly participates in the 
process of atherogenesis by modulating endothelial function [69]. CRP, at 
concentrations known to predict cardiovascular events, induces the expression 
of VCAM-1, ICAM-1, selectins, and MCP-1 in cultured endothelial cells via 
increased secretion of ET-1, a potent endogenous vasoconstrictor, and IL-6 . 
CRP attenuates basal and stimulated endothelial NO production by 
downregulating endothelial NO synthase mRNA and protein expression[70]. The 
diminished NO activity may in turn inhibit angiogenesis, an important 
compensatory response in chronic ischemia. Furthermore, in vascular smooth 
muscle cells, CRP upregulates angiotensin type 1 receptor (AT1-R) mRNA and 
protein levels and increased AT1-R expression on the cell surface . The AT1-R 
is a key atherosclerotic switch that facilitates ANG II-induced reactive oxygen 
species production, vascular smooth muscle cell migration and proliferation, 
and vascular remodeling [71]. Interestingly, the effect of CRP on endothelial 
dysfunction is potentiated by hyperglycemia, and these effects are attenuated by 
rosiglitazone, an insulin-sensitizing thiazolidinedione (TZD) antidiabetic drug . 
Direct Comparisons of  HSCRP With Other Novel Markers of Vascular Risk [72] 
Testing for homocysteine and lipoprotein(a), both of which are involved 
in atherothrombosis, have been recommended for certain high-risk groups. For 
example, homocysteine evaluation is recommended among those with impaired 
methionine metabolism due to renal failure or hypothyroidism, whereas 
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lipoprotein(a) assessment has been recommended for those with premature 
atherosclerosis in the absence of other risk factors.  
Three large-scale prospective studies have compared directly the relative 
efficacy of homocysteine screening to HSCRP evaluation. In each study, 
magnitude of risk prediction associated with HSCRP levels in the top quintile 
was greater than that associated with similar elevations of homocysteine.  
  
High Sensitivity C-Reactive Protein 
Standard clinical assays for CRP typically have a lower detection limit of 
3 to 8 mg/L. Thus, these assays lack sensitivity within the low-normal range and 
cannot be used effectively for vascular risk prediction. In recognition of this 
limitation, initial epidemiological studies used research-based assays designed 
to determine CRP levels with excellent fidelity and reproducibility across the 
normal range. Several such “high-sensitivity” or “ultra-sensitive” assays for 
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CRP are now commercially available, and formal standardization programs 
have been undertaken to ensure comparability across hs-CRP assays. 
Reference Range for hs-CRP 
 Less than 1.0 mg/L = Low Risk for CVD  
 1.0 – 2.9 mg/L = Intermediate Risk for CVD  
 Greater than 3.0 mg/L High Risk for CVD  
Other conditions in which hs-CRP is elevated 
hs-CRP is non specific, and is elevated in a number of other conditions like, 
 Malignancy 
 Connective tissue disease 
 Infection 
 Inflammatory bowel disease (IBD) 
 SLE 
 Pneumococcal pneumonia 
 Rheumatoid arthritis 
 Acute Rheumatic fever 
 Tuberculosis 
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MATERIALS & METHODS 
 
 
 
(a) SUBJECTS 
 
Case Group: Patients with subclinical hypothyroidism attending 
Endocrinology Outpatient Department and those who are inpatients in Rajiv 
Gandhi Government General Hospital, Chennai. 
 
Control Group: Patients who are Euthyroid and matched with cases in 
terms of age, sex and height, and not having any of the exclusion criteria.  
 
(b) PERIOD OF STUDY 
6 months 
 
(c) DESIGN OF STUDY 
Cross-sectional study 
 
(d) CONSENT                      
Informed consent from all patients         
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(e) ELIGIBILITY CRITERIA 
CASES : Patients with subclinical hypothyroidism based on serum 
TSH and free T4 levels, attending Endocrinology OPD and those who are 
inpatients in Government General Hospital, Chennai. 
 
CONTROLS : Patients who are euthyroid, based on serum TSH 
and free T4 levels, attending Endocrinology OPD or those admitted for 
diseases other than those listed in exclusion criteria, with normal thyroid 
profile. 
 
(f) EXCLUSION CRITERIA 
 Patients who are already on thyroxine replacement therapy. 
 Patients with coexisting Diabetes mellitus and Hypertension. 
 Patients with rheumatological disorders. 
 Patients who have fever of any cause. 
 Patients taking any medication that can raise hs-CRP levels 
(NSAIDs/Statins/HRT). 
 Patients who have undergone any surgery in the recent past. 
 Patients with recent trauma. 
 Patients who are smokers. 
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 Patients who already have Coronary Artery Disease. 
 
(g) METHODOLOGY 
                Patients with subclinical hypothyroidism based on serum TSH and 
free T4 levels were carefully selected, based on the inclusion  and exclusion 
criteria. Complete and relevant history was elicited and a thorough general and 
systemic examination was done as per proforma. Blood samples were collected 
after overnight fast, and analysed for the required parameters. The same 
protocol was followed for controls.  
 
(h) Investigation details                       
                Complete history and examination was done. Blood / Serum samples 
were collected after overnight fast for Complete Blood Count, Fasting Blood 
Sugar, Renal Function Tests, Liver Function Tests, Lipid Profile (Total 
cholesterol, Triglycerides and HDL), High Sensitivity C-Reactive Protein (by 
turbidometry), ECG and Echocardiogram if necessary.   
 
(i) Data Collection And Methods                
               Collection of data as per proforma with consent from Cases and 
Controls in Medicine wards and OP department.                                                                                                                
 Analysis           :            Data analyzed using statistical Package-SPSS  software 
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(h) Normal Values of parameters Assessed[15]      
 TSH         :              0.34–4.25 mIU/L 
 Free T4     :           0.7–1.24 ng/dL 
 Free T3     :           2.4–4.2 pg/mL 
 Fasting Plasma Glucose :          75-100 mg/dl 
Total Cholesterol  :  Less than 200 mg/dl 
Triglycerides          :   30-200 mg/dl 
HDL Cholesterol   :  40-60 mg/dl 
High Sensitivity C-Reactive Protein (based on the risk for atherosclerosis): 
                    Low Risk           :     Less than 1 mg/l 
                    Intermediate Risk : 1-2.9 mg/l 
                    High Risk      : More than or equal to 3 mg/l 
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OBSERVATIONS 
                                       
(1) AGE DISTRIBUTION 
(A) CASES 
Table 1. showing age distribution among cases 
AGE NUMBER 
<20 1 
21-30 17 
31-40 11 
41-50 14 
51-60 5 
>60 2 
TOTAL 50 
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       Among cases, most were aged between 21 to 30 years (34%), and the least 
number of cases were found in extremes of age, i.e. less than 20 (2%) and more 
than 60 years (4%) of age. In a broader sense, the bulk of the cases were 
constituted by 21 to 50 years of age.  
(B) CONTROL GROUP 
 
Table 2. showing age distribution among controls 
AGE NUMBER 
<20 0 
21-30 10 
31-40 18 
41-50 15 
51-60 5 
>60 2 
TOTAL 50 
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Among controls, most were aged between 31 to 40 years (36%), and the least 
number of cases were found in extremes of age, i.e. less than 20 (0%)  and more 
than 60 years (4%) of age. Like cases, in a broader sense, the bulk of the cases 
were constituted by 21 to 50 years of age. 
 
 
 
 
 
[53] 
 
(2) SEX DISTRIBUTION 
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Among cases, females predominated, constituting 90% of total cases. Since we 
chose controls matched with cases for sex also, the sex distribution of controls 
is exactly the same as cases, i.e 90% females and 10% males. 
 
 
3) THYROID PROFILE 
 
Table 3. Comparing mean levels of TSH, T4 and T3 among cases and  
controls 
 
 CONTROLS CASES 
TSH 2.22 8.35 
FREE T4 0.99 0.92 
FREE T3 3.17 3.07 
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From the above table and diagram, it is inferred that the levels of TSH are 
above normal in cases and within normal limits in controls. Levels of  Free T4 
and Free T3 are within normal limits in both cases and controls, but the mean 
levels of both are slightly on the lower side in cases, when compared to 
controls. 
 
 
 
 
 
 
 
[56] 
 
TSH LEVELS IN CASES 
Table 4. showing TSH levels among cases, taking 10 as the cut-off 
 
GREATER THAN 10 40 
LESS THAN 10 10 
 
 
 
                Levels of TSH among cases below 10 mIU/ml constituted the  
maximum, with 40 out of 50 cases in this range (80%).   
 
 
[57] 
 
(5) COMPARISON OF LIPID PROFILE OF CASES AND CONTROL 
 
Table 5. showing mean levels of Total cholesterol, Triglycerides and HDL 
among controls and cases 
 
  CONTROLS CASES 
TOTAL CHOLESTEROL 138.98 167.56 
TRIGLYCERIDES 122.02 142.06 
HDL 44.88 38.8 
 
 
From the above table and diagram, it is inferred that mean values of Total 
cholesterol and Triglycerides are higher among cases than controls. Mean value 
of HDL was lower among cases.  
[58] 
 
 
6) RISK STRATFICATION OF CASES AND CONTROLS BASED ON  
    BMI 
Table 6. comparing the cases and controls by Body Mass Index, stratified 
into classes of obesity 
 
CLASS BMI CONTROLS CASES 
UNDERWEIGHT <18.5 1 0 
HEALTHY 
WEIGHT 18.5-24.9 27 20 
OVERWEIGHT 25-29.9 19 24 
OBESITY CLASS I 30-34.9 3 6 
OBESITY CLASS II 35-39.9 0 0 
OBESITY CLASS III >40 0 0 
 TOTAL 50 50 
 
 
[59] 
 
 
From the above table and diagram, it is inferred that in both case and control 
group, most of the individuals are clustered in the ‘healthy weight’ and 
‘overweight’ category, as far as BMI is concerned. A few of them are in the 
category of Class I obesity. One person in the control group is underweight. 
None among the cases or controls are in Class II or III obesity. 
                 It is also inferred that the proportion of individuals in the ‘healthy 
weight’ group is lower among cases when compared to controls. Also, the 
proportion of individuals in the ‘over weight’ and class I obesity are higher 
among cases when compared to controls. 
 
 
7) hs-CRP LEVELS OF VARYING SEVERITY AMONG CASES AND  
    CONTROLS 
 
Table 7. Comparison of cases and controls by hs-CRP, stratified into risk 
groups 
hs-CRP CONTROLS CASES 
<1 37 18 
1 TO 3 8 25 
>3 5 7 
TOTAL 50 50 
[60] 
 
 
 
 
 
From the above table and diagram, it is inferred that the number of cases 
with levels of hs-CRP in the intermediate and High risk range, is obiously 
higher among than controls. In the low risk range, control group have more 
number than cases. 
 
 
 
 
 
 
 
 
[61] 
 
STATISTICAL ANALYSIS 
(A) Analysis of cases and controls in terms of age: 
 
TABLE 8. 
 
From the above table, it is inferred that there is no statistically significant 
association between cases and controls in terms of age as the p value is >0.05. 
 
 
 
 
 
  
CONTROLS 
 
CASES 
 
P  VALUE 
 
MEAN 
 
S.D. 
 
MEAN 
 
S.D. 
 
AGE 
 
39.44 
 
10.5 
 
39.04 
 
11.31 
 
0.855 
[62] 
 
 
(B) Analysis of cases and controls in terms of height, weight and BMI 
TABLE 9. 
 
From the above table, it is inferred that there is no statistically significant 
association between cases and controls in terms of height as the p value is >.05. 
But there is statistically  significant association in terms of weight and BMI as 
the p value is <0.05. 
 
 
 
 
 
 CONTROLS CASES P    
VALUE MEAN S.D. MEAN S.D. 
HEIGHT 1.59 0.07 1.59 0.07 0.566 
WEIGHT 61.96 8.91 66.14 10.16 .031 
BMI 25.09 3.47 25.02 3.41 0.036 
[63] 
 
(C) Analysis of cases and controls in terms of Waist Hip Ratio 
TABLE 10. 
 
From the above table, it is inferred that there is no statistically significant 
association between cases and controls in terms of  Waist and Hip  
circumference and waist/hip ratio as  the p value is >0.05. 
 
 
 
 
 
 CONTROLS CASES P    
VALUE MEAN S.D. MEAN S.D. 
WAIST 
CIRCUMFERENCE 
82.74 10.1 83.76 11.35 0.636 
HIP 
CIRCUMFERENCE 
91.96 9.25 91.64 11.49 0.88 
WAIST HIP RATIO 0.9 0.09 0.91 0.1 0.509 
[64] 
 
(D) Analysis of cases and controls in terms of Blood Pressure 
TABLE 11. 
 
From the above table, it is inferred that there is no statistically significant 
association between cases and controls in terms of Blood pressure, as the p  
value is >0.05. 
 
 
 
 
 
 
BLOOD 
PRESSURE 
CONTROLS CASES P    
VALUE MEAN S.D. MEAN S.D. 
SYSTOLIC 
BP 
114.12 4.36 115.08 6.44 0.385 
DIASTOLIC 
BP 
75.2 4.99 75.48 5.1 0.782 
[65] 
 
(E) Analysis of cases and controls in terms of Lipid Profile 
TABLE 12. 
 
From the above table, it is inferred that there is statistically significant 
association between cases and controls in terms of Total cholesterol, HDL  
cholesterol and Triglycerides, as the p value is <0.05. 
 
 
 
 
 
LIPID PROFILE CONTROLS CASES P    
VALUE MEAN S.D. MEAN S.D. 
TOTAL 
CHOLESTEROL 
138.98 53.54 167.56 42.41 0.004 
HDL 
CHOLESTEROL 
44.88 7.33 38.8 8.32 0.000 
TRIGLYCERIDE 122.02 28.7 142.06 50.51 0.017 
[66] 
 
(F)  Analysis of cases and controls in terms of Thyroid Profile 
TABLE 13. 
 
From the above table, it is inferred that there is statistically significant 
association between cases and controls in terms of TSH, as the p  
value is <0.05.There is no statistically significant association between cases  
and controls in terms of Free T4 and Free T3, as the p value is >0.05. 
(G) Analysis of cases and controls in terms of hs-CRP 
TABLE 14. 
THYROID 
FUNCTION 
TESTS 
CONTROLS CASES P    
VALUE MEAN S.D. MEAN S.D. 
TSH 2.22 1.02 8.35 2.26 0.000 
FREE T4 0.99 0.17 0.92 0.16 0.036 
FREE T3 3.17 0.61 3.07 0.53 0.431 
 CONTROLS CASES P    
VALUE MEAN S.D. MEAN S.D. 
hsCRP 1.15 1.2 1.93 1.49 0.005 
[67] 
 
 
From the above table, it is inferred that there is statistically significant 
association between cases and controls in terms of hs-CRP, as the p  
value is <0.05. 
ANALYSIS OF CORRELATION OF VARIABLES STUDIED WITH HS  
CRP 
Table 15. 
S.NO COMPARED PARAMETERS 
F 
VALUE 
P 
VALUE 
1 AGE AND hs-CRP 0.825 0.682 
2 TSH AND hs-CRP 58.35 0.00 
3 FT4 AND hs-CRP 1.24 0.41 
4 FT3 AND hs-CRP 1.06 0.51 
5 
TOTAL CHOLESTEROL AND hs-
CRP 
0.65 0.81 
6 TRIGLYCERIDES AND hs-CRP 1.29 0.38 
7 HDL AND hs-CRP 0.78 0.71 
8 BMI AND hs-CRP 0.57 0.87 
9 W/H RATIO AND hs-CRP 1.16 0.45 
[68] 
 
 
From the above table, it is inferred that there is statistically significant 
correlation between TSH levels and hs-CRP, as the p value is <0.05. The other 
variables, like age, Free T4, Free T3, Total cholesterol, Triglycerides, HDL, 
Body Mass Index and Waist/Hip ration did not show any correlation with HS-
CRP, as the p value is >0.05. 
 
Table 16. 
 
Statistical parameter TSH HS-CRP 
TSH 
Pearson Correlation 1 0.856 
N 50 50 
Significance (2 tailed) 0.000 0.000 
HSCRP 
Pearson Correlation 0.856 1 
N 50 50 
Significance (2 tailed) 0.000 0.000 
 
Tests for the association between TSH and hs-CRP also showed that there 
is a strong association between the two, as the p value is <0.05. 
                                    
[69] 
 
                                                   DISCUSSION 
    A case group consisting of 62 patients of biochemically evident 
subclinical hypothyroidism defined by serum TSH and Free T4 levels were 
considered for the study. Of these, 12 patients were excluded from the study as 
they had other comorbid illnesses, or were already taking Levo thyroxine. The 
remaining 50 patients were labelled as Cases. 
   Control group for the study consists of carefully chosen euthyroid 
subjects who are matched with the cases for age, sex and height. They were also 
included in the study after carefully evaluating for the presence or absence of 
any of the exclusion criteria. 
Both the cases and controls were subjected to complete relevant history 
and physical examination, including anthropometry. Fasting samples of blood 
and serum were collected for the analysis of Complete Blood Count, Renal 
Function Tests, Liver Function Tests, Lipid Profile, Fasting Blood Sugar and 
High Sensitivity CRP assay. The parameters were tabulated and analyzed. 
A similar study has been conducted by Alpaslan et al[77]. in Turkey, 
where they have analyzed the levels of hs-CRP in patients with subclinical 
hypothyroidism. In the study, they have included plasma insulin levels, HOMA-
IR index and serum prolactin levels. Due to limited financial resources, we 
could not include these in our study. 
[70] 
 
(1) POPULATION CHARACTERISTICS 
          There have been suggestions that age [73] and gender[74] may have an 
impact on IHD risk in people with SCH, but no quantitative analysis has been 
performed to investigate this. The prevalence increases with age, and in 
women older than 60 years, subclinical hypothyroidism is present in up 
to 20%.[75]The data are less consistent in men; in those older than 65 
years, the prevalence increases and approaches that of women in some, 
but not all, studies.[76] 
In our study, the age distribution of subclinical hypothyroidism shows a 
characteristic pattern, with most cases occurring in the age range of 21 to 30 
years. This was closely followed by 41-50 years of age. 80% of cases were 
woman, which is consistent with the prevalence of Subclinical hypothyroidism 
in most of the studies. The mean ages for cases and controls, respectively in our 
study are 39.04+11.3 and 39.44+10.5. This is slightly higher than the mean ages 
of study and control population of the study conducted by Alpaslan et al[77]. 
                    
(2) THYROID PROFILE  
Mean levels of TSH, for controls and cases in our study, respectively, are 
2.22+2.26 and 8.3+1.02 uIU/ml. This pattern resembles the same in the study 
[71] 
 
conducted by Alpaslan et al. [77], in which the mean values are 1.5 and 7.4, 
respectively. 
Though by definition, Subclinical hypothyroidism is characterised by 
elevated TSH and normal free T4 levels, most studies indicate that values of 
TSH are less than 10 mIU/l in most cases. In a study conducted by Toft et al., 
approximately 75% had values lower than 10 mIU/L(4).Our study also 
reflects this pattern of TSH, with 80% of cases having less than 10 mIU/l. 
        Most studies on subclinical hypothyroidism indicate that although Free T3 
and T4 are normal in this condition by definition, they are on the lower normal 
range. This is also shown in our study with lower level of mean values of both 
hormones in cases when compared to controls. In the study conducted by 
Alpaslan et al., the mean values of Free T4 in cases and controls, respectively, 
are 1.18+0.22 and 1.38+0.26, and in our study, they are 0.99+0.17 and 
0.92+0.16. 
(3) SERUM hs-CRP LEVELS 
Number of cases with Mean levels of hs-CRP in the intermediate and 
High risk range, was obiously higher among than controls. In the low risk range, 
control group had more number than cases. This obviously shows that persons 
in the case group have a high prevalence of hs-CRP when compared to case. 
This is consistent with the study conducted by Alpaslan et al. [77] 
[72] 
 
     The mean values of hs-CRP among controls is 1.93+1.49, which is 
similar to the value in the same study. But the mean value of hs-CRP in cases in 
our study (1.93) is lower than the same in that study (4.2).   
 
(4) LIPID PROFILE 
Mean value of Total cholesterol (cases – 167.5+42.4controls-138.9+53.5) 
and Triglycerides (cases – 142.06+52.5,controls-122.02+28.7) was found to be 
higher among cases than controls. Mean value of HDL (cases – 
38.8+8.32,controls-44.8+7.3) was lower among cases.  
In the study conducted by Alpaslan et al[77] ., significant association was 
found only in Total and LDL cholesterol level. In our study, significant 
association was found for Total cholesterol, LDL cholesterol and HDL 
cholesterol between cases and controls, with the later lower in cases than 
controls. 
   The mean values of Triglycerides and HDL are similar to those in the 
study conducted by Alpaslan et al., but the mean value of Total cholesterol in 
our study, both in cases and controls are notably lower than those in the said 
study. 
 
(5) CORRELATION BETWEEN hs-CRP AND OTHER VARIABLES 
Analysis of correlation between hs-CRP and other variables was done. 
The parameters compared with hs-CRP for correlation are : age, sex, Total 
[73] 
 
cholesterol, Triglycerides, HDL cholesterol, BMI and Waist Hip ratio.It was 
found that there was statistically significant positive correlation and association 
between TSH and hs-CRP levels. This is consistent with the study conducted by 
Alpaslan et al. [77],which also showed a positive association between the same. 
The other parameters did not show a significant association with hs-CRP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
[74] 
 
                               SUMMARY AND CONCLUSION  
It is concluded that 
1. Subclinical hypothyroidism has a predilection to affect females much more       
commonly than males. 
2. Though the definition of subclinical hypothyroidism includes high TSH and 
normal free T4, most patients with this condition have a TSH value of less than 
10 mIU/l and both free T4 and free T3 in the low normal range. 
3. Prevalence of Elevated levels of High Sensitivity C-Reactive Protein is more 
among individuals with Subclinical hypothyroidism. The prevalence of those in 
the high risk for Cardiovascular Disease is also alarmingly high. 
4. Prevalence of overweight and Class I obesity is more in Subclinical 
hypothyroidism. 
5. Mean levels of Total Cholesterol and Triglycerides are high, and HDL levels 
are low in patients with Subclinical hypothyroidism. 
6. There is a positive correlation between serum TSH levels and hs-CRP levels. 
          From conclusions 3,4,5 and 6, it is clear that patients with subclinical 
hypothyroidism are more prone for Atherosclerotic Cardiovascular diseases. 
Hence, it is prudent to screen for this condition among those with other risk 
factors for coronary artery disease. Also, in patients with established Subclinical 
[75] 
 
hypothyroidism, estimation of High Sensitivity C-Reactive Protein provides a 
cost effective method of screening patients at increased risk for Atherosclerotic 
Coronary Artery disease. Early institution of Thyroxine replacement may 
prevent or delay the onset of the same. 
 
[76] 
 
BIBLIOGRAPHY 
1. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An 
epidemiological perspective. 
Indian J Endocr Metab [serial online] 2011 [cited 2011 Dec 26];15:78-81.   
2. Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A 
Summary of the Evidence for the U.S. Preventive Services Task Force  
Mark Helfand (2004) 
Ann Intern Med 140:128-141 
3. Subclinical Thyroid Disease: Scientific Review and Guidelines for  
Diagnosis and Management 
M Gillett - 2004 
JAMA 2004;291: 228–38 
4. Hypothyroidism and Atherosclerosis 
Anne R. Cappola , Paul W. Ladenson 
The Journal of Clinical Endocrinology & Metabolism June 1, 2003 vol.  
88 no. 6 2438-2444 
5. Tunbridge, w. M. G., evered, d. C., hall, r., appleton, d., brewis, m., clark, 
f., evans, j. G., young, e., bird, t. And smith, p. A. (1977), the spectrum of 
thyroid disease in a community: the whickham survey. Clinical 
endocrinology, 7: 481–493. Doi: 10.1111/j.1365-2265.1977.tb01340.x  
[77] 
 
6. Razvi et al. The incidence of ischemic heart disease and mortality in 
people with subclinical hypothyroidism: Reanalysis of the Whickham 
survey cohort. J. Clin. Endocrinol. Metab. 2010; 95:00-00 [Epub 
February 11, 2010].   
7. Ridker PM. Clinical application of  C-reactive protein for cardiovascular 
disease detection and prevention.  
Circulation 2003; 107: 363–369  
8. High-Sensitivity C-Reactive Protein  
Potential Adjunct for Global Risk Assessment in the Primary Prevention 
of Cardiovascular Disease  
Paul M. Ridker, MD, MPH  
Circulation. 2001;103:1813.   
9.  Williams Textbook of Endocrinology-11th edition 
Henry M.Kronenberg, Shlomo Melmed, Kenneth  
 S.Polonsky, P.Reed Larson  
10. Ericson LE: Exocytosis and endocytosis in the thyroid follicle cell.  Mol 
Cell Endocrinol  1981; 22:1-24.  
11. Textbook of Medical Physiology- Eleventh Edition 
Arthur C. Guyton, M.D., John E. Hall, Ph.D. 
12. Ganong’s Review of Medical Physiology, 23e  
[78] 
 
 Kim E. Barrett, Susan M. Barman, Scott Boitano, Heddwen Brooks 
13. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 
2000;10(4):321-330  
14. The epidemiology of hypothyroidism--an update.  
Bilous RW, Tunbridge WM. 
Baillieres Clin Endocrinol Metab. 1988 Aug;2(3):531-40.  
15. Harrison's Principles of Internal Medicine – 18th Edition.            
 Longo, Fauci, Kasper, Hauser, Jamson, Loscalzo 
16. The Clinical Significance of Subclinical Thyroid Dysfunction  
Bernadette Biondi, David S. Cooper 
Endocr Rev 2008 29: 76-131  
17. Bemben DA, Hamm RM, Morgan L, et al. Thyroid disease in the elderly.    
Part 2. Predictability of subclinical hypothyroidism. J Fam Pract 1994; 
38:583. 
18. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 
55 years. A study in an urban US community. Arch Intern Med 1990; 
150:785.  
19. Kanaya AM, Harris F, Volpato S, et al. Association between thyroid 
dysfunction and total cholesterol level in an older biracial population: the 
health, aging and body composition study. Arch Intern Med 2002; 
162:773.  
[79] 
 
20. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado 
thyroid disease prevalence study. Arch Intern Med 2000; 160:526.  
21. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of 
abnormal thyrotrophin (TSH) concentrations in the elderly in the United 
Kingdom. Clin Endocrinol (Oxf) 1991; 34:77.  
22. Szabolcs I, Podoba J, Feldkamp J, et al. Comparative screening for 
thyroid disorders in old age in areas of iodine deficiency, long-term 
iodine prophylaxis and abundant iodine intake. Clin Endocrinol (Oxf) 
1997; 47:87.  
23. Subclinical Hypothyroidism and Autoimmune  Thyroiditis in Pregnancy 
 - A Study in South Indian Subjects  
R Gayathri, S Lavanya, K Raghavan 
japi • october 2009 • vol. 57     
24. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients  
with hyperthyroidism and hypothyroidism: Standards of Care Committee, 
American Thyroid Association. JAMA . 1995;273:808-812.  
25. AACE Thyroid Task Force. American Association of Clinical 
Endocrinologists medical guidelines for clinical practice for the 
evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr 
Pract . 2002;8:457-469. 
[80] 
 
26. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the  
elderly: microsomal antibodies as discriminant for therapy. JAMA . 
1987;258:209-213.  
27. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous 
course of subclinical hypothyroidism: prognostic value of thyrotropin,  
thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab . 
2002;87:3221-3226.  
28. Kinlaw WB 1991 Atherosclerosis and the thyroid. Thyroid Today. 14:1–
8  
29. Bastenie PA, Vanhaelst L, Neve P 1967 Coronary artery disease in 
hypothyroidism: observation in preclinical myxoedema. Lancet 2:1221–
1222  
30. Fowler PBS, Swale J, Andrews H 1970 Hypercholesterolaemia in 
borderline hypothyroidism: stage of premyxoedema. Lancet 2:488–491  
Hak AE, PolsHAP, Visser TJ,DrexhageHA,Hofman A,Witteman  
JCM2000 Subclinical hypothyroidism is an independent risk factor for 
atherosclerosis andmyocardial infarction in elderlywomen: The 
Rotterdamstudy. Ann Intern Med 132:270–278  
31. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M 2000 Changes in 
[81] 
 
lipoprotein(a) levels in overt and subclinical hypothyroidism before and 
during treatment. Thyroid 10:803–808 
32. Caron P, Calazel C, Parra HJ, Hoff M, Louvet JP 1990 Decreased HDL 
cholesterol in subclinical hypothyroidism: the effect of levothyroxine 
therapy. ClinEndocrinol (Oxf) 33:519–523  
33. Arem R, Patsch W 1990 Lipoprotein and apolipoprotein levels in 
subclinical hypothyroidism. Effect of levothyroxine therapy. Arch Intern 
Med 150:2097–2100  
34. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, 
DreweJ, Huber P, Herzog R, Muller B 2001 TSH-controlled l-thyroxine  
therapy reduces cholesterol levels and clinical symptoms in subclinical 
hypothyroidism: a double-blind, placebo-controlled trial (Basel Thyroid 
Study). J ClinEndocrinol Metab 86:4860–4866  
35. Lipoprotein Profile in Subclinical Hypothyroidism:Response to 
 Levothyroxine Replacement, a Randomized Placebo-Controlled Study 
nadia caraccio, ele ferrannini, and fabio monzani   
The Journal of Clinical Endocrinology & Metabolism 87(4):1533–1538 
36. Lindeman RD, Schade DS, LaRue A, et al. Subclinical hypothyroidism 
in a biethnic, urban community. J Am Geriatr Soc 1999;47(6):703-9.  
37. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. 
Subclinical hypothyroidism is an independent risk factor for 
[82] 
 
atherosclerosis and myocardial infarction in elderly women: the 
Rotterdam Study. Ann Intern Med 2000;132(4):270-8.  
38. Vanderpump MP, Tunbridge WM, French JM, et al. The development of  
ischemic heart disease in relation to autoimmune thyroid disease in a 20-
year follow-up study of an English community. Thyroid 1996;6(3):155-
60.  
39. Nedrebo BG, Ericsson UB, Nygard O, et al. Plasma total homocysteine  
 levels in hyperthyroid and hypothyroid patients. Metabolism 
 1998;47(1):89-93. 
40. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. 
Hyperhomocysteinemia and hypercholesterolemia associated with 
hypothyroidism in the third US National Health and Nutrition 
Examination Survey. Atherosclerosis 2001;155(1):195-200.  
41. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. 
Determinants of changes in plasma homocysteine in hyperthyroidism and 
hypothyroidism. Clin Endocrinol 2001;54(2):197-204.  
42. Lien EA, Nedrebo BG, Varhaug JE, Nygard O, Aakvaag A, Ueland PM. 
Plasma total homocysteine levels during short-term iatrogenic 
hypothyroidism. J Clin Endocrinol Metab 2000;85(3):1049-53.  
43. Catargi B, Parrot-Roulaud F, Cochet C, Ducassou D, Roger P, Tabarin 
A. Homocysteine, hypothyroidism, and effect of thyroid hormone 
replacement. Thyroid 1999;9(12):1163-6.  
[83] 
 
44. Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN, 
Garry PJ. Impact of subclinical hypothyroidism on serum total 
homocysteine concentrations, the prevalence of coronary heart disease 
(CHD), and CHD risk factors in the New Mexico Elder Health Survey. 
Thyroid 2003;13(6):595-600.  
45. Eden S, Sundbeck G, Lindstedt G. et al. Screening for thyroid disease in 
the elderly. Serum concentrations of thyrotropin and 3,5,3'-
triiodothyronine in a representative population of 79-year-old women and 
men. Comp Gerontol. 1988;2:40–45.  
46. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg P A, Lindstedt 
G. A double-blind cross-over 12-month study of L-thyroxine treatment of 
women with ‘subclinical’ hypothyroidism. Clin Endocrinol. 1988;29:63–
75.  
47. Lindeman R D, Schade D S, LaRue A. et al. Subclinical hypothyroidism 
in a biethnic, urban community. J Am Geriatr Soc. 1999;47:703–709. 
48. Canaris G J, Manowitz N R, Mayor G, Ridgway E C. The Colorado 
thyroid disease prevalence study. Arch Intern Med. 2000;160:526–534.  
49. Cooper D S, Halpern R, Wood L C, Levin A A, Ridgway E C. L-
Thyroxine therapy in subclinical hypothyroidism. A double-blind, 
placebo-controlled trial. Ann Intern Med. 1984;101:18–24.  
50. Cooper D S. Clinical practice. Subclinical hypothyroidism. N Engl J 
Med. 2001;345:260–265.  
[84] 
 
51. Fahrenfort J J, Wilterdink A M, van der Veen E A. Long-term residual 
complaints and psychosocial sequelae after remission of hyperthyroidism. 
Psychoneuroendocrinology. 2000;25:201–211.  
52. Allan W C, Haddow J E, Palomaki G E. et al. Maternal thyroid 
deficiency and pregnancy complications: implications for population 
screening. J Med Screen. 2000;7:127–130.  
53. Haddow J E, Palomaki G E, Allan W C. et al. Maternal thyroid 
deficiency during pregnancy and subsequent neuropsychological 
development of the child. N Engl J Med. 1999;341:549–555.  
54. Subclinical Hypothyroidism: Deciding When to Treat 
victor adlin, 
Am Fam Physician. 1998 Feb 15;57(4):776-780.  
55. Subclinical Thyroid Disease 
george r. wilson, r. whit curry, jr., 
Am Fam Physician. 2005 Oct 15;72(8):1517-1524. 
56. Surks  MI, Ortiz  E, Daniels  GH, Sawin  CT, Col  NF, Cobin  RH, et al. 
 Subclinical thyroid disease: scientific review and guidelines for 
diagnosis and management.  JAMA.  2004;291:228–38.  
57. Roti  E, Minelli  R, Gardini  E, Braverman  LE.  The use and misuse of 
thyroid hormone.  Endocr Rev.  1993;14:401–23.  
[85] 
 
58. Sawin  CT, Geller  A, Wolf  PA, Belanger  AJ, Baker  E, Bacharach  P, 
et al.  Low serum thyrotropin concentrations as a risk factor for atrial 
fibrillation in older persons.  N Engl J Med.  1994;331:1249–52.  
59. Ross  DS.  Hyperthyroidism, thyroid hormone therapy, and bone. 
 Thyroid.  1994;4:319–26.  
60. Thompson, D; Pepys, MB; Wood, SP (February 1999). "The 
physiological structure of human C-reactive protein and its complex with 
phosphocholine". Structure 7 (2): 169–77.  
61. Pepys, MB; Hirschfield, GM (June 2003). "C-reactive protein: a critical 
update" (PDF). J Clin Invest 111 (12): 1805–12.  
62. Lau, DC; Dhillon, B; Yan, H; Szmitko, PE; Verma, S (May 2005). 
"Adipokines: molecular links between obesity and atheroslcerosis". Am J 
Physiol Heart Circ Physiol 288 (5): H2031–41.  
63. Mantovani A, Garlanda C, Doni A, Bottazzi B (January 2008). 
"Pentraxins in innate immunity: from C-reactive protein to the long 
pentraxin PTX3". J. Clin. Immunol. 28 (1): 1–13.  
64. Tillett WS, Francis T (September 1930). "Serological reactions in 
pneumonia with a nonprotein somatic fraction of pneumococcus"  
65. John J. Ratey MD; Gary A. Noskin MEd MD; MD, Ralph Braun; 
Edward N. Hanley Jr MD; Iain B. McInnes; Shaun Ruddy MD (2008). 
Kelley's Textbook of Rheumatology: 2-Volume Set, Expert Consult: 
[86] 
 
Online and Print (Textbook of Rheumatology (Kelley's)(2 Vol)). 
Philadelphia: Saunders. ISBN 1-4160-3285-1.  
66. Pepys, M.B. & G.M. Hirschfield (2003) J. Clin. Invest.111:1805.  
67. Woo, P. et al. (1985) J. Biol. Chem. 260:13384.  
68. Inflammation and atherosclerosis 
Peter Libby, Paul M. Ridker, Attilio Maseri,  
Circulation. 2002; 105: 1135-1143 
69. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon 
B, and Mickle DA. Endothelin antagonism and interleukin-6 inhibition 
attenuate the proatherogenic effects of C-reactive protein. Circulation 
105: 1890–1896, 2002.  
70. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, 
Dhillon B, Weisel RD, Li RK, Mickle DA, and Stewart DJ. A self-
fulfilling prophecy: C-reactive protein attenuates nitric oxide production 
and inhibits angiogenesis. Circulation 106: 913–919, 2002.  
71. Nickenig G and Harrison DG. The AT1-type angiotensin receptor in 
oxidative stress and atherogenesis. Part I: oxidative stress and 
atherogenesis. Circulation 105: 393–396, 2002. 
72. High-Sensitivity C-Reactive Protein Potential Adjunct for Global Risk 
Assessment in the Primary Prevention of Cardiovascular Disease   
 
[87] 
 
73. JAMA 292:2591–2599 
Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, 
Westendorp RG 2004 Thyroid status, disability and cognitive function, 
and survival in old age. 
74. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC 
2000:Subclinical hypothyroidism is an independent risk factor for 
atherosclerosis and myocardial infarction in elderly women: the 
Rotterdam Study. Ann Intern Med 132:270–278 
75. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado 
Thyroid Disease Prevalence Study. Arch Intern Med. 2000;160:526-
534.pmid:10695693 
76. Lindeman RD, Schade DS, LaRue A, Romero LJ, Liang HC, 
Baumgartner RN, 
Koehler KM, Garry PJ 1999 Subclinical hypothyroidism in a biethnic, 
urban community. J Am Geriatr Soc 47:703–709 
77. Subclinical hypothyroidism may be associated with Elevated High 
Sensitive C-Reactive Protein (Low grade inflammation) and fasting hyper 
insulinemia 
Alpaslan et al. 
Endocrine Journal 2005,(1, 89-94) 
INSTITUTE OF INTERNAL MEDICINE 
MMC & RGGGH, CHENNAI-3 
                  “A STUDY ON THE PREVALENCE OF ELEVATED HIGH 
SENSITIVITY C-REACTIVE PROTEIN IN PATIENTS WITH 
SUBCLINICAL HYPOTHYROIDISM” -   PROFORMA 
 
NAME :                                                                     ADDRESS : 
AGE/SEX : 
OCCUPATION :                                                        PHONE NO. 
SYMPTOMS 
Poor appetite          :               Y   /   N 
Constipation           :               Y   /   N 
Cold intolerance      :               Y   /   N 
Weight gain             :               Y   /   N 
Chest pain               :               Y   /   N 
Breathlessness         :               Y   /   N 
Palpitation               :               Y   /   N 
Swelling of legs        :              Y   /   N 
Syncope                   :              Y   /   N 
Fever                        :              Y   /   N 
PAST HISTORY 
Diabetes :                                       Systemic Hypertension:                       CAD : 
Stroke/TIA:                                     CKD :                                                       TB:   
Surgery:                                          Rheumatological disorder:                  Trauma: 
PERSONAL HISTORY  
Smoker :                                                                 Alcoholic : 
DRUG HISTORY: 
whether on L- thyroxine replacement:   Y   /   N                   NSAIDs:   Y   /   N 
Statins:   Y   /   N                                                                         Others:   Y   /   N 
MENSTRUAL HISTORY: 
 
GENERAL EXAMINATION 
PULSE :                                               BP :                                                   
WEIGHT:                                            HEIGHT :                                      BMI :                                     
WAIST CIRCUMFERENCE:                                   HIP CIRCUMFERENCE: 
WAIST/HIP :    
FEATURES OF HYPOTHYROIDISM: 
Dry skin:                            Hoarse Voice:                      cool peripheral extremities: 
Carpal tunnel syndrome: 
NECK:     Goitre:                                         Surgical scar: 
SYSTEMS: 
CVS                : 
RS                  : 
ABDOMEN   : 
CNS               :   Delayed tendon reflex relaxation 
 
INVESTIGATIONS: 
1. COMPLETE BLOOD COUNT 
Total count 
Differential count  : P                   L                  E                   M                 B 
Haemoglobin:                    gms% 
ESR: 
Platelets: 
2. RENAL FUNCTION TESTS 
Blood urea: 
Fasting blood sugar: 
Serum creatinine: 
Serum sodium: 
Serum potassium: 
 
 
3. LIVER FUNCTION TESTS 
Total bilirubin:                            Direct bilirubin: 
SGOT:                                         SGPT:                                
Alkaline phosphatase: 
Total protein:                               Albumin: 
4. THYROID PROFILE: 
            TSH :                            
             FREE T4 :                       FREE T3 :                            
5. BLOOD SUGAR : 
              FASTING :                                             POST PRANDIAL : 
6. FASTING LIPID PROFILE : 
          TOTAL CHOLESTEROL:                                 TG:                       
          HDL:                                                                 LDL: 
 
 
7. High Sensitive C-Reactive Protein: 
                         Value : 
            Risk category : 
8. ECG in all leads : 
 
9. Echocardiogram : 
 
 
FINAL IMPRESSION: 
 
              MASTER CHART CASES 
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1 27 F 6.4 1.14 2.5 0.45 148 268 42 1.78 86 27.1 100.8 105.6 0.95 120 80 
2 25 F 5.72 1.13 3.05 0.2 185 90 38 1.5 73 32.4 88.9 96.5 0.92 108 76 
3 27 F 7.25 1.21 2.68 0.9 173 167 49 1.52 71 30.7 83.6 94.4 0.89 120 80 
4 55 F 6.4 1.22 2.8 0.5 148 137 42 1.52 55 23.8 83.7 105.6 0.79 104 70 
5 45 F 8.58 0.8 2.93 2.4 165 162 45 1.6 72 28.1 97.7 102.5 0.95 116 68 
6 42 M 7.31 0.89 2.87 1.3 266 177 34 1.57 71 28.8 94.6 102.8 0.92 120 80 
7 30 F 10.61 0.72 3.21 2.84 184 260 35 1.65 77 28.3 90.6 96.5 0.94 118 68 
8 50 F 9.56 0.78 3.1 2.95 168 124 49 1.75 70 22.9 98.1 99.3 0.99 102 76 
9 30 F 7.84 1.14 2.52 2.2 165 82 45 1.61 64 24.7 84 94 0.89 112 80 
10 37 F 14.4 0.98 2.75 2.49 91 160 38 1.57 71 28.8 103.1 117.1 0.88 110 70 
11 46 F 11.85 1.17 2.9 4.65 192 86 42 1.55 66 27.5 99.1 109.2 0.77 116 68 
12 29 F 9.83 0.95 2.59 3.9 61 208 40 1.58 60 24 85.6 101.4 0.84 124 80 
13 47 M 5.07 0.83 3 0.03 195 79 47 1.54 68 28.7 81.3 88.2 0.92 120 80 
14 30 F 6.71 1.12 2.86 0.8 144 159 36 1.74 72 23.8 74.8 83.4 0.9 118 78 
15 30 F 7.6 0.8 3.05 1.57 148 96 51 1.62 73 27.8 92.4 101.1 0.91 110 80 
16 37 F 8.44 1.12 3.25 2.4 87 136 22 1.53 54 23.1 68.4 79.5 0.86 118 68 
17 22 F 9.1 1.09 4.11 2.7 149 149 43 1.48 59 26.9 71.1 76.2 0.93 120 80 
              MASTER CHART CASES 
 
18 63 F 9 0.86 3.9 2.6 148 132 37 1.68 68 24.1 96.5 112.9 0.85 108 78 
19 59 F 11.29 0.85 4.1 1.55 181 195 38 1.48 57 26 68 73.6 0.92 122 76 
20 36 F 12.57 1.21 3.73 5.4 207 215 20 1.59 68 26.9 70.5 86.5 0.82 120 80 
21 38 F 13.75 0.72 2.45 5.7 149 106 42 1.58 52 20.8 71.1 81.2 0.88 120 80 
22 42 F 8.1 0.84 2.91 2.27 196 142 48 1.63 59 22.2 86.6 105.3 0.82 110 70 
23 47 F 12.06 0.76 2.54 4.96 148 144 27 1.56 46 18.9 66.4 84.1 0.79 124 78 
24 56 F 5.7 1.23 3.72 0.2 256 158 22 1.57 60 24.3 68.9 87.6 0.79 100 68 
25 30 F 6.4 1.2 2.72 0.57 177 126 40 1.63 81 30.5 98.1 83.8 1.17 118 80 
26 40 F 7.68 0.81 2.5 1.9 246 136 39 1.57 52 21.1 78 90 0.87 118 76 
27 24 F 9.7 0.7 2.54 2.97 120 104 40 1.59 66 26.1 70.3 79.9 0.88 100 70 
28 28 M 6.08 0.75 3.8 0.4 162 131 38 1.62 71 27.1 88.6 90.7 0.98 120 76 
29 48 F 7.55 0.71 2.93 1.5 175 83 41 1.76 94 30.4 102.6 104.3 0.98 116 70 
30 28 F 8.65 0.78 4 2.4 73 167 24 1.71 55 18.8 68.7 86.9 0.79 110 70 
31 35 F 9.06 0.77 3.6 2.7 140 86 37 1.55 62 25.8 71.9 80.4 0.89 120 80 
32 39 F 9.46 0.85 2.96 2.89 188 156 36 1.67 58 20.8 77.9 91.1 0.86 110 70 
33 46 F 9.89 0.75 2.61 2.16 163 67 44 1.48 68 31 83.8 87.6 0.96 120 80 
34 23 F 5.15 0.92 2.46 0.06 92 115 20 1.47 63 29.2 71.1 76.2 0.93 120 80 
35 52 M 7.04 0.99 4.13 0.7 157 97 42 1.55 77 32.1 91.3 75.5 1.21 112 70 
36 49 F 5.75 1.11 3.24 0.21 144 152 43 1.61 74 28.6 83.6 97.8 0.85 116 70 
37 65 M 10.53 0.97 2.42 4.2 221 130 38 1.51 62 27.2 89.3 91.4 0.98 120 80 
38 55 F 7.3 0.76 2.68 0.99 183 64 42 1.69 72 25.2 73.5 83 0.89 116 70 
39 46 F 6.01 0.94 2.72 0.3 180 142 48 1.63 76 28.6 89.5 71.2 1.26 120 80 
40 38 F 7.42 0.88 4.04 1.4 198 178 31 1.62 65 24.8 67.8 83.3 0.81 110 80 
41 34 F 6.78 0.74 2.67 0.62 178 140 44 1.47 55 25.5 85 83 1.02 100 70 
42 40 F 5.79 1.1 3.1 0.22 184 108 47 1.56 72 29.6 90.4 73.8 1.22 116 86 
43 28 F 7.6 0.73 3.44 1.8 168 240 43 1.44 39 18.8 71.1 83.8 0.85 104 68 
44 29 F 5.89 0.78 2.51 0.33 212 62 58 1.57 59 23.9 69.4 88.1 0.79 120 80 
45 49 F 8.07 0.88 2.99 2.7 180 147 28 1.64 66 24.5 89.4 105.2 0.85 116 78 
46 20 F 10.8 0.91 2.63 4.6 169 106 40 1.71 82 28 93.9 95.9 0.98 118 78 
47 26 F 11.85 0.78 3.9 1.74 203 221 48 1.6 70 27.3 93.2 94 0.99 120 70 
              MASTER CHART CASES 
 
 48 42 F 8.39 0.92 3.47 2.35 234 189 28 1.61 75 28.9 96.2 104.6 0.92 118 70 
49 49 F 7.35 0.91 3.79 1.3 131 94 36 1.63 57 21.5 70.4 84.3 0.84 116 80 
50 39 F 6.55 0.96 2.59 0.57 146 230 33 1.65 64 23.5 97.2 112 0.87 120 80 
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1 43 F 2.25 1.2 3.51 0.73 110 80 42 1.48 40 18.3 71.7 84.8 0.85 110 70 
2 32 F 4.04 1.16 2.62 0.99 97 75 45 1.54 56 23.6 72.6 79.4 0.91 110 80 
3 38 F 1.15 0.95 4.19 0.26 90 140 57 1.5 59 26.2 67.8 73.3 0.92 116 70 
4 42 F 2.78 1.09 2.56 2.2 244 118 49 1.62 59 22.5 83 95 0.87 118 76 
5 31 F 3.27 1.1 2.44 0.8 257 126 52 1.55 61 25.4 86.6 89.3 0.97 118 70 
6 42 F 3.98 1.08 2.7 0.6 159 137 54 1.49 56 25.2 72.6 80.8 0.9 116 70 
7 43 M 1.89 0.72 2.86 0.54 121 167 30 1.52 55 23.8 84.6 93.4 0.91 116 68 
8 45 F 0.55 0.93 4.13 0.62 139 139 40 1.61 54 20.8 76.8 91.3 0.84 110 70 
9 33 F 3.12 0.72 2.5 0.79 74 101 54 1.68 60 21.3 89.8 104 0.86 110 80 
10 64 F 3.49 0.8 2.47 3.7 186 172 43 1.51 61 26.8 84.8 95.4 0.89 120 70 
11 28 F 1.36 0.82 2.52 0.93 160 146 46 1.55 54 22.5 75.1 81.2 0.92 110 70 
12 32 F 0.87 0.91 2.96 0.89 73 132 47 1.57 55 22.3 70.5 85.3 0.83 116 70 
13 54 M 1.06 1.18 2.57 0.75 162 159 28 1.71 71 24.3 99.5 83.9 1.19 110 80 
14 48 F 0.76 1.24 2.68 3.3 114 92 46 1.52 57 24.7 90.7 106 0.86 120 80 
15 58 F 1.55 0.78 2.83 0.4 88 141 49 1.65 68 25 95.8 103 0.93 110 80 
16 33 F 2.24 1.05 4.09 0.69 148 150 57 1.56 64 26.3 82.6 94.4 0.88 120 80 
17 37 F 3.63 0.75 3.93 0.5 168 116 54 1.78 69 21.8 94.5 96.6 0.98 118 76 
18 35 F 4.09 1.18 3.61 0.74 149 208 55 1.52 57 24.7 75.9 85.4 0.89 110 70 
19 52 F 1.18 1.24 2.47 0.3 156 115 47 1.54 54 22.8 69.7 87.8 0.79 120 80 
20 64 F 2.61 1.11 3.94 1.4 138 94 58 1.59 54 21.4 71.7 78.5 0.91 110 80 
 
                                                                       MASTER CHART ( CONTROLS) 
 
 21 37 F 1.46 0.72 4.18 0.42 75 126 48 1.62 66 25.2 90.7 107 0.85 120 80 
22 30 M 2.97 0.94 2.71 1.2 286 132 43 1.57 75 30.4 93.4 98.8 0.95 110 70 
23 32 F 1.98 1.09 2.44 0.1 140 107 50 1.73 86 28.7 101 105 0.97 120 80 
24 29 F 2.83 0.81 3.47 0.44 82 113 45 1.6 65 25.4 94.4 103 0.92 120 80 
25 46 F 1.5 1.03 2.52 0.21 111 141 54 1.65 60 22 69.4 84 0.83 116 70 
26 48 F 3.54 0.94 4.15 2.5 148 95 49 1.53 61 26.1 86.1 102 0.84 110 70 
27 34 F 2.65 1.12 2.75 0.36 107 86 46 1.62 83 31.6 99.7 84.3 1.18 110 80 
28 25 F 2.46 0.87 2.43 0.88 90 103 48 1.58 63 25.2 97.5 106 0.92 116 70 
29 42 F 3.96 1.14 3.86 4.6 82 154 48 1.62 59 22.5 72.9 87.7 0.83 110 80 
30 25 F 1.69 0.89 2.84 0.38 300 118 45 1.6 73 28.5 89.4 93.2 0.96 120 80 
31 59 F 3.2 0.77 2.41 1.9 163 147 25 1.7 55 19 69.3 89.7 0.77 110 70 
32 35 F 1.55 1.22 2.66 1.5 99 97 46 1.53 61 26.1 87.4 90.5 0.97 110 80 
33 40 F 2.84 0.8 4 0.5 159 117 35 1.51 61 26.8 75.5 89 0.85 110 80 
34 27 F 0.86 0.89 2.56 0.23 116 187 42 1.55 46 19.2 69.1 87.3 0.79 120 80 
35 22 F 2.21 0.92 2.91 0.33 149 86 35 1.7 60 20.8 73.2 83 0.88 110 70 
36 47 M 3.44 0.75 2.76 2.9 213 98 47 1.63 76 28.6 84.7 99.9 0.85 110 80 
37 34 F 3.38 1.04 2.6 0.92 96 116 45 1.49 57 25.7 72.8 86.4 0.84 116 70 
38 39 F 0.83 1.12 3.88 0.23 150 159 32 1.52 67 29 94.2 79.3 1.19 120 80 
39 24 M 1.98 0.76 4.03 0.87 162 86 38 1.55 60 25 72.7 86.8 0.84 110 80 
40 42 F 1.4 0.9 3.69 5.3 120 124 39 1.57 54 21.9 69.4 88.5 0.78 118 80 
41 33 F 2.75 1.24 3.56 0.15 215 129 45 1.66 72 26.1 95.2 103 0.93 110 70 
42 29 F 1.04 0.84 2.92 0.77 139 114 47 1.7 72 24.9 74.1 86 0.86 120 80 
43 26 F 1.65 1.19 3.12 0.99 87 95 45 1.57 75 30.4 89.3 99.9 0.89 110 80 
44 44 F 2.43 1.2 3.24 0.5 168 109 49 1.6 59 23.1 85.1 105 0.81 116 70 
45 47 F 1.71 1.02 4.07 0.65 94 128 36 1.57 56 22.7 86.2 106 0.82 110 70 
46 60 F 0.56 1.12 3.43 4.2 73 137 42 1.5 51 22.7 70.6 76.3 0.93 120 80 
47 40 F 2.81 1.21 3.39 0.73 80 102 45 1.67 66 23.7 89.2 106 0.84 116 70 
48 41 F 1.81 0.91 2.93 0.72 133 100 43 1.63 76 28.6 90.5 99.3 0.91 110 80 
49 35 F 2.98 1.04 3.53 0.39 152 85 39 1.58 62 24.8 88.9 94.1 0.94 110 70 
50 46 F 0.94 1.23 3.91 1.6 127 102 40 1.46 57 26.7 88.7 84 1.06 110 70 
PATIENT CONSENT FORM 
Study detail: “A STUDY ON THE PREVALENCE OF ELEVATED HIGH 
SENSITIVITY C-REACTIVE PROTEIN IN PATIENTS WITH SUBCLINICAL 
HYPOTHYROIDISM” 
Study centre  :             Rajiv Gandhi Government general hospital, Chennai. 
Patients Name  : 
Patients Age : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being 
or any unexpected or unusual symptoms. 
I hereby consent to participate in  this study. 
I hereby  give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. 
Signature/thumb impression:    
Patients Name and Address:                   Place   Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place   Date      
